Fredrik Tiberg, PhD

President and CEO
Camurus, Sweden

Poster(s):

• (19) Dosing to effect with Subcutaneous and Sublingual Buprenorphine for Opioid Use Disorder
  Friday, April 5, 2024

  9:45 AM – 1:15 PM